Cytokinetics CYTK Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's change in other liabilities?
- Cytokinetics (CYTK) reported change in other liabilities of -$3.95M in Q1 2026.
- How has Cytokinetics's change in other liabilities changed year-over-year?
- Cytokinetics's change in other liabilities decreased by 343.9% year-over-year, from $1.62M to -$3.95M.
- What is the long-term trend for Cytokinetics's change in other liabilities?
- Over 2 years (2022 to 2025), Cytokinetics's change in other liabilities has grown at a 24.1% compound annual growth rate (CAGR), from -$4.06M to -$6.25M.
- What does change in other liabilities mean?
- The net change in miscellaneous debts or obligations.
- How do you interpret change in other liabilities?
- Large fluctuations may indicate non-recurring events or changes in long-term accounting estimates.
- How does change in other liabilities compare across companies?
- Varies significantly based on company-specific legal or tax structures.